A View of BioAtla Inc. (BCAB) Stock’s Fundamentals and Valuations

As of right now, BioAtla Inc. [BCAB] is trading at $4.08, up 12.71%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCAB shares have gain 21.43% over the last week, with a monthly amount drifted -50.61%, and not seem to be holding up well over a long-time horizon.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


On 10, January 2023, BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones. In a post published today on Yahoo Finance, Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled.

From an analyst’s perspective:

BioAtla Inc. [NASDAQ: BCAB] stock has seen the most recent analyst activity on September 15, 2022, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $17. Previously, Credit Suisse downgraded its rating to Neutral on May 05, 2022, and dropped its price target to $5. On March 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. ROTH Capital initiated its recommendation with a Buy and recommended $75 as its price target on June 28, 2021.

Through the last year, BioAtla Inc.’s stock price ranged from $2.01 to $12.15. Currently, Wall Street analysts expect the stock to reach $26.14 within the next 12 months. BioAtla Inc. [NASDAQ: BCAB] shares were valued at $4.08 at the most recent close of the market. An investor can expect a potential return of 540.69% based on the average BCAB price forecast.

Analyzing the BCAB fundamentals

Gross Margin for this corporation currently stands at -432.00% with Operating Margin at -38576.00%, Pretax Margin comes in at -38160.80%, and Net Margin reading is -38160.80%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.73 points at the first support level, and at 3.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.28, and for the 2nd resistance point, it is at 4.49.

BioAtla Inc. [BCAB] reported earnings per share of -$0.77 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.69/share, meaning a difference of -$0.08 and a surprise factor of -11.60%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.65 per share as compared to estimates of -$0.67 per share, a difference of $0.02 representing a surprise of 3.00%.

Ratios To Look Out For

It is important to note that BioAtla Inc. [NASDAQ:BCAB] has a current ratio of 7.70. On the other hand, the Quick Ratio is 12.48, and the Cash Ratio is 12.36. Considering the valuation of this stock, the price to sales ratio is 2,713.75, the price to book ratio is 3.47.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 2 insider purchases totaling 5,700 shares and 9 insider sales totaling 7,573 shares over the past 3 months. Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Dec 19 when 3700.0 shares were purchased. Director, MCBRINN SYLVIA completed a deal on Nov 22 to buy 2000.0 shares. Meanwhile, Director MCBRINN SYLVIA bought 1000.0 shares on Sep 13.